- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
The immunocompromised dermatology patient and COVID-19
Author(s):
In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.
In light of the ongoing pandemic, Vivian Shi, M.D., assistant professor of dermatology at the University of Arizona College of Medicine, Tucson, Ariz., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.
References:
Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5):e173-e175.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
